Saturday, 19 November 2016
Are Neurontin And Lyrica Really The Best Options For Neuropathic Pain
Today's post from wellnessresources.com (see link below) is an out and out attack on Lyrica (pregabalin) and neurontin as drugs for neuropathic symptoms. However, it has to be said, it's now wildly out of date. Nevertheless, the prophetic warnings in the article have been borne out. It was written in 2009 and since then the FDA has issued strong warnings about Lyrica...and Pfizer (the manufacturers) have themselves withdrawn positive advice for its use in tackling diabetic and HIV-related neuropathy. Yet, these drugs are still universally popular and widely prescribed by doctors. Is this a case of heavy promotion by the drug company, or a refusal to face the facts on the part of health professionals? Unfortunately, Lyrica is one of those drugs that seems to have a multi-function and is prescribed for all sorts of nerve problems. It is so deeply entrenched in the lexicon of nerve problem treatments that subsequent warnings, law suits and withdrawals of support from its own maker, have had little effect on its popularity. If your doctor or neurologist wants to prescribe Lyrica for you, it may be time to pose some serious questions, especially if your neuropathy stems from diabetes or HIV-related causes. There are alternatives which may be safer for you in the long run. More articles on this subject can be found by typing in 'Lyrica' in the search box to the right of this blog.
Neurontin and Lyrica are a Death Sentence for New Brain Synapses
Byron J. Richards, Board Certified Clinical Nutritionist Wednesday, October 14, 2009
Neurontin and its newer more potent version, Lyrica, are widely used for off-label indications that are an outright flagrant danger to the public. These blockbuster drugs were approved for use even though the FDA had no idea what they actually did in the brain. A shocking new study shows that they block the formation of new brain synapses1, drastically reducing the potential for rejuvenating brain plasticity – meaning that these drugs will cause brain decline faster than any substance known to mankind.
The problem of these drugs is compounded by their flagrant illegal marketing. Neurontin was approved by the FDA for epilepsy back in 1994. The drug underwent massive illegal off-label promotion that cost Warner-Lambert 430 million dollars (the very first big fine for off-label promotion). The drug is now owned by Pfizer. Pfizer also owns Lyrica, a super-potent version of Neurontin. It has been approved by the FDA for various types of pain and fibromyalgia. Lyrica is one of four drugs which a subsidiary of Pfizer illegally marketed, resulting in a $2.3 billion settlement against Pfizer.
Even though the marketing of these drugs has been heavily fined, they continue to rack up billions in sales from the off-label uses. Doctors use them for all manner of nerve issues because they are good at suppressing symptoms. However, such uses can no longer be justified because the actual mechanism of the drugs is finally understood and they are creating a significant long-term reduction in nerve health.
The researchers in the above study try to downplay the serious nature of the drugs by saying “adult neurons don’t form many new synapses.” That is simply not true. The new science is showing that brain health during aging relies on the formation of new synapses. Even these researchers managed to question the common use of these medications in pregnant women. How is a fetus supposed to make new nerve cells when the mother is taking a drug that blocks them?
These are the kind of situations the FDA should be all over. As usual, the FDA is sitting around pondering a suicide warning for Lyrica while its off-label uses include bi-polar disorder and migraine headaches. The FDA is likely to twiddle its thumbs for the next decade on the brain damage issue. Consumer beware.
http://www.wellnessresources.com/freedom/articles/neurontin_and_lyrica_are_a_death_sentence_for_new_brain_synapses/
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: only a member of this blog may post a comment.